Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis

Patricia A. Jorquera, Lydia Anderson, Ralph A. Tripp

Research output: Contribution to journalReview articlepeer-review

31 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) is the most important cause of lower respiratory tract infections causing bronchiolitis and some mortality in young children and the elderly. Despite decades of research there is no licensed RSV vaccine. Although significant advances have been made in understanding the immune factors responsible for inducing vaccine-enhanced disease in animal models, less information is available for humans. In this review, we discuss the different types of RSV vaccines and their target population, the need for establishing immune correlates for vaccine efficacy, and how the use of different animal models can help predict vaccine efficacy and clinical outcomes in humans.

Original languageEnglish
Pages (from-to)173-187
Number of pages15
JournalExpert Review of Vaccines
Volume15
Issue number2
DOIs
Publication statusPublished - 1 Feb 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis'. Together they form a unique fingerprint.

Cite this